Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2010 Jun;30(2):117-22.
doi: 10.1097/WNO.0b013e3181d8e4af.

Pegylated interferon alpha-associated optic neuropathy

Affiliations
Case Reports

Pegylated interferon alpha-associated optic neuropathy

Kathleen T Berg et al. J Neuroophthalmol. 2010 Jun.

Abstract

A 52-year-old man with chronic hepatitis C presented with painless, bilateral, simultaneous nonarteritic anterior ischemic optic neuropathy (NAION) and peripheral neuropathy. Symptoms began 19 weeks after starting peginterferon alpha-2a. The peripheral neuropathy and vision of the right eye improved, but the vision of the left eye worsened after stopping interferon. We identified 23 additional cases of NAION during interferon alpha therapy. At least 12 of these patients suffered bilateral NAION. Patients lost vision 1-40 weeks after initiating therapy. Of 21 eyes that had documented initial and follow-up acuities, 8 improved, 1 worsened, and the rest remained stable. One patient had a painful peripheral neuropathy. Treatment with interferon alpha may result in NAION. Discontinuation of therapy deserves consideration after weighing individual risks and benefits.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any financial/conflicting interests to disclose. The sponsor or funding organization had no role in the design or conduct of this research.

Figures

FIG. 1
FIG. 1
Bilateral optic disc edema is present with a flame hemorrhage (arrow) on the left eye.
FIG. 2
FIG. 2
Initial visual fields show an inferior arcuate defect in the right eye and a normal result in the left eye.
FIG. 3
FIG. 3
Four weeks later, visual fields reveal slight progression of field loss in the right eye and an inferior altitudinal defect with central involvement in the left eye.

Similar articles

Cited by

References

    1. Baron S, Tyring SK, Fleischmann WR, Jr, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ, Hughes TK. The interferons. Mechanisms of action and clinical applications. JAMA. 1991;266:1375–1383. - PubMed
    1. Bailon P, Palleroni A, Schaffer CA, Spence CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem. 2001;12:195–202. - PubMed
    1. Berenguer J, Gonzalez-Garcia J, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, Bellon JM, Esteban JH GESIDA HIV/HCV Cohort. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother. 2009;63:1256–1263. - PubMed
    1. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Bacon BR, Davis MN, Mukhopadhyay P, Kuory K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593. - PubMed
    1. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283–291. - PubMed

Publication types

MeSH terms